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1. Introduction 
Dental plaque is a complex microbial biofilm that forms at high cell density in the oral cavity 
by the successive accumulation of hundreds of different species of bacteria. Both host 
immune and bacterial factors are involved in the progression from healthy to diseased state 
in plaque biofilm, and in the oral cavity, gingival epithelial cells (GECs) are one of the first 
host cell types that encounter colonizing bacteria. As a consequence, GECs respond to the 
presence of bacteria through an elaborate signaling network, producing antimicrobial 
peptides (AMPs) and cytokines, leading to host innate immune responses. Periodontal 
disease is a consequence of the imbalance between the pathogenic potential of the biofilm 
and host immune defense properties, resulting in an inflammatory reaction of the 
periodontium. As a part of host defense mechanism, GECs secrete specific endogenous 
serine protease inhibitors to prevent tissue damage from excessive proteolytic enzyme 
activity due to inflammation. Recent studies showed GECs induced different serine 
protease inhibitors in the presence of non-pathogenic bacteria, but these protease 
inhibitors were attenuated by periopathogens, whose main virulence factors are 
proteases. Furthermore, periodontal patients with periopathogens present in their plaque 
exhibited significantly lower protease inhibitors in gingival crevicular fluid in comparison 
to healthy controls. The degradation of protease inhibitors by periopathogens may result 
in decreased host protective capacity, and the balance between cellular protease inhibitors 
and their degradation by periodontal pathogens may be an important factor in 
susceptibility to breakdown from chronic infection. In addition to bacterial infection, 
genetic and environmental factors contribute to occurrence and progression of 
periodontal disease. Recent studies suggest that the manifestation and severity of 
periodontal disease may be influenced by epigenetic factors. Many patients with the same 
clinical symptoms respond differently to the same therapy, suggesting the inter-
individual variability observed as a clinical outcome of the disease is influenced by 
genetic as well as epigenetic factors. 
In this chapter, we will closely examine the mechanisms gingival epithelia utilize in 
inducing AMPs in response to bacterial presence and assess future therapeutic potential of 
AMPs. We will also focus on the impact the balance between the proteases and protease 
inhibitors has on oral health and how epigenetic modifications brought on by exposure to 
periodontal pathogens affect the progression of periodontal disease. 
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2. Microbial biofilm and innate immune responses of gingiva 
Dental plaque is a complex microbial biofilm that forms at high cell density on tooth 
surfaces in the oral cavity by the successive accumulation of over 500 different species of 
bacteria (Kolenbrander, Andersen et al. 2002; Rickard, Gilbert et al. 2003). The early 
colonizers of the tooth surface are mainly non-pathogens comprised of Gram-positive 
facultative organisms, including Streptococcus gordonii, Streptococcus sanguis and Streptococcus 
oralis. These initial colonizers adhere to salivary pellicle on teeth, leading to successive 
colonization of Gram-negative anaerobes such as Fusobacterium nucleatum and finally to 
pathogens such as Porphyromonas gingivalis. The formation of plaque has been linked to the 
human oral diseases, caries and periodontitis (Socransky, Smith et al. 2002; Socransky and 
Haffajee 2005), and both host immune and bacterial factors are involved in the progression 
from healthy to diseased state in plaque biofilm.  
Periodontitis is one of most common inflammatory diseases and can be of inflammatory, 
traumatic, metabolic, developmental and/or genetic origin. In most cases, periodontal 
disease results in an inflammatory reaction of the periodontium to pathogenic 
microorganisms. Among various species of microorganisms making up oral biofilm that 
accumulates on the tooth surface adjacent to the gingiva, Gram-negative anaerobic bacteria 
P. gingivalis, Tannerella forsythia and Treponema denticola in particular have been strongly 
associated with periodontal disease (Socransky, Haffajee et al. 1998; Armitage 1999; 
Socransky and Haffajee 2003). Bacteria first form a supra-gingival biofilm attached to the 
tooth surface, and once they have passed the junctional epithelium, bacteria may enter the 
gingival crevice to form sub-gingival biofilm, which provides an optimal environment for 
anaerobic bacteria to colonize and reproduce (Socransky and Haffajee 2003). The number of 
Gram-negative anaerobic bacteria increases during development and maturation of the 
dental biofilm. Both host immune and bacterial factors are involved in the progression from 
healthy to diseased state in plaque biofilm, thus periodontal disease is the result of the 
imbalance between the pathogenic potential of the biofilm and host immune defense 
properties. In addition, genetic and/or environmental factors, such as smoking, contribute 
to occurrence and progression of periodontal disease (Michalowicz, Aeppli et al. 1991; 
Michalowicz, Diehl et al. 2000; Kinane and Hart 2003; Loos, John et al. 2005).  
P. gingivalis is an aggressive pathogen and considered an etiologic agent of severe adult 
periodontitis. Colonization of the oral cavity by P. gingivalis is facilitated by adherence to 
various oral surfaces, including epithelial cells, the salivary pellicle that coats tooth surfaces, 
and other oral bacteria that comprise the plaque biofilm (Socransky and Haffajee 1992). 
However, P. gingivalis is considered a secondary colonizer of plaque and rarely colonizes the 
tooth surface until initial plaque bacteria, such as S. gordonii, establish an appropriate 
environment. Adhesion between S. gordonii and P. gingivalis is mediated by S. gordonii cell-
surface protein SspB and P. gingivalis minor fimbriae (Chung, Demuth et al. 2000). In the 
oral cavity, gingival epithelial cells are one of the first host cell types that encounter 
colonizing bacteria. As a consequence, epithelial cells respond to the presence of bacteria 
through an elaborate signaling network, producing antimicrobial peptides and cytokines, 
and at times stimulating apoptotic cell death. This bacterial-host communication takes place 
via a number of signal transduction pathways, but different bacteria may induce different 
signals from the host. Conversely, various host immune responses may interfere with the 
way commensals and pathogens communicate to form biofilm, although this means of 
defense is poorly understood.  
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Periodontal disease is of importance not only in oral health, but also in general health 
because of its association with an increased risk of preterm births and low birth weight 
babies (Offenbacher, Katz et al. 1996; Buduneli, Baylas et al. 2005). Thus, it is of importance 
to understand how oral bacteria alter host innate immune responses and how periodontal 
disease is affected by protective factors induced by the host. 
3. The role of Antimicrobial Peptides in periodontal health 
3.1 Antimicrobial Peptides (AMPs) 
In the presence of diverse environment of microbial consortiums, epithelia express several 
natural antimicrobial peptides (AMPs) which work synergistically with a broad spectrum 
of activity against both Gram-negative and Gram-positive bacteria, as well as against 
yeast and some virus to maintain balance between health and disease (Hancock and 
Chapple 1999; Lehrer and Ganz 2002; Premratanachai, Joly et al. 2004). AMPs are small 
cationic peptides with molecular weights typically ranging between 3,500 and 6,500 Da 
(Dale 2002). They adopt amphiphilic topologies, which allows them to interact and 
selectively disrupt microbial cell membranes (Som, Vemparala et al. 2008). In humans 
these antimicrobial peptides include defensins and a cathelicidin family member LL-37 in 
skin and oral mucosa and other epithelia (Hancock and Scott 2000; Lehrer and Ganz 2002; 
Selsted and Ouellette 2005). The human defensins include the alpha-defensins of intestinal 
and neutrophil origin, and the beta-defensins of skin and oral mucosa and other epithelia. 
Alpha-defensins are expressed in neutrophils as part of their non-oxidative antimicrobial 
mechanisms (Lehrer, Lichtenstein et al. 1993; van Wetering, Sterk et al. 1999). Alpha-
defensins are also found in Paneth cells in the intestine (Selsted 1992; Ouellette 1999). 
They are synthesized as precursors that are proteolytically activated and released during 
inflammation (Rock 1998; Wilson, Ouellette et al. 1999). The human beta-defensins (hBDs) 
are small, cationic antimicrobial peptides made primarily by epithelial cells and expressed 
in all human epithelia tested to date (Dale 2002). The beta-defensins are secreted in 
biological fluids, including urine, bronchial fluids, nasal secretions, saliva and gingival 
crevicular fluid (Valore, Park et al. 1998; Cole 1999; Sahasrabudhe 2000; Diamond, 
Kimball et al. 2001). hBDs were first identified in tracheal epithelial cells and subsequently 
found in many epithelia including kidney and urinary tract, oral mucosa and skin 
(Diamond, Russell et al. 1996; Zhao, Wang et al. 1996; Krisanaprakornkit, Weinberg et al. 
1998; Valore, Park et al. 1998). 
The expression of the cathelicidin, LL-37, is found in human tongue, buccal mucosa and 
saliva following inflammatory stimulation (Frohm Nilsson, Sandstedt et al. 1999; 
Murakami, Ohtake et al. 2002). It is kept inactive until proteases cleave the conserved 
proregion (Zanetti, Gennaro et al. 2000). Immunohistochemistry studies found that LL-37, 
derived from neutrophils, was detected in the junctional epithelium (Dale, Kimball et al. 
2001). The defensins and LL-37 are localized in different sites in gingiva, which suggests 
that they may play different roles in specific sites in which they are expressed (Dale, 
Kimball et al. 2001). Because these AMPs have synergistic effects, their presence in saliva 
may provide natural antimicrobial barrier (Tao, Jurevic et al. 2005). Different sites within 
the oral cavity where various AMPs are predominantly expressed are depicted in  
Figure 1. 
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Fig. 1. Various sites in the oral cavity where different AMPs are predominantly expressed. 
Dale and Fredericks 2005; permission from Horizon Scientific Press 
3.1.1 Alpha-defensins  
Alpha- and beta-defensins are peptides with six disulfide-linked cysteines. Structurally, the 
difference between the two defensins lies within the length of peptide segments between the 
six cysteines and pairing of the cysteines (Bals and Wilson 2003). Six different human alpha-
defensins have been identified so far, including four human neutrophil peptides, HNP1-4, 
and two others known as human defensins 5 and 6 (HD-5, HD-6) (Ganz, Selsted et al. 1985; 
Ganz and Lehrer 1994; Cunliffe 2003). Alpha-defensins are arginine-rich and localized in 
either neutrophil azurophilic granules or Paneth cells, which are the epithelia of the 
intestinal mucosa. During gingivitis, neutrophils dominate the lesion area, but the relative 
proportion compared to plasma cells and lymphocytes in neutrophils decreases during the 
transition to periodontitis (Kinane and Bouchard 2008; Nussbaum and Shapira 2011). 
Disorders in neutrophil production have been associated with destruction of periodontal 
tissue and eventual periodontal disease (Crawford, Wilton et al. 2000). Within neutrophils, 
human alpha-defensins are abundant and work together with the oral epithelium to provide 
a barrier to microbial colonization, particularly in the junctional epithelium of the tooth 
surface (Dale and Fredericks 2005). Studies have shown that two periodontal pathogens, P. 
gingivalis and Aggregatibacter actinomycetemcomitans, as well as non-pathogenic commensal 
bacteria S. gordonii are insensitive to alpha-defensin activity (Miyasaki, Bodeau et al. 1990; 
Zhong, Yang et al. 1998; Raj, Antonyraj et al. 2000). However, when extra amino acids were 
added to the N-terminus and C-terminus end of HNP2, an enhanced antibacterial activity 
against the same bacteria was shown, indicating the structural anatomy is a crucial 
determinant in this AMP’s antibacterial activity (Raj, Antonyraj et al. 2000).  
HNP 1-3 are detected in the junctional epithelium and the gingival crevicular fluid (GCF), 
and GCF from patients with aggressive and chronic periodontitis showed significantly 
elevated levels of HNP 1-3 compared to healthy patients (McKay, Olson et al. 1999; Dale, 
Kimball et al. 2001). Interestingly, the increased concentration of both alpha- and beta-
defensins was correlated in patients with chronic periodontitis with the amount of 
periodontal pathogens P. gingivalis, T. denticola, and T. forsythia (Puklo, Guentsch et al. 2008). 
Recently, HNP1 and HNP2 were shown to decrease the response of pro-inflammatory 
cytokine IL-6, while enhancing antibody response to specific P. gingivalis adhesin in mice 
(Kohlgraf, Ackermann et al. 2010). Thus, alpha-defensins may play a key role as a mediator 
of innate immunity in gingiva against periopathogenic microbes.  
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3.1.2 Beta-defensins  
Beta-defensins 1 and 2 (hBD-1 and hBD-2) are found in normal, uninflamed gingival tissues 
as part of the innate host defense mechanism (Krisanaprakornkit, Weinberg et al. 1998; Dale, 
Kimball et al. 2001). Furthermore, hBD-1 and hBD-2 are localized at the gingival margin 
where there is the most exposure to oral bacteria of the plaque on the tooth surface, but not 
in the junctional epithelium. Thus, the junctional epithelium is protected by alpha-defensins 
and LL-37 released from neutrophils, while the differentiated, stratified epithelia are 
protected by beta-defensins. Structurally a reduced hBD-1 differs from an oxidized hBD-1, 
and a reduction in the disulfide bridges of hBD-1 causes the peptide to become a potent 
AMP against opportunistic pathogen Candida albicans and Lactobacillus species (Schroeder, 
Wu et al. 2011). A structural modulation of hBD-1, dependent on the environment it exists in 
the oral cavity, could shield the healthy epithelium against colonization by commensal and 
periopathogenic bacteria. However, compared to other beta-defensins, hBD-1 only shows a 
minor effect against oral bacteria, such as P. gingivalis, A. actinomycetemcomitans, Prevotella 
intermedia, and F. nucleatum (Ouhara, Komatsuzawa et al. 2005).  
In oral epithelia, the expression of hBD-2 is found in normal, uninflamed gingival tissues 
and is induced by various bacteria (Krisanaprakornkit, Kimball et al. 2000; Dale, Kimball et 
al. 2001; Chung and Dale 2004). The expression of hBD-2 after challenge from a commensal 
bacterium indicates that the normal oral epithelium is already at a heightened state to 
combat potentially harmful pathogens (Krisanaprakornkit, Kimball et al. 2000; Chung and 
Dale 2004).  
hBD-3 has shown bactericidal activity against a wide range of oral bacteria, including 
periodontal pathogens A. actinomycetemcomitans and P. gingivalis, and cariogenic bacteria 
Streptococcus mutans (Maisetta, Batoni et al. 2003). Furthermore, both normal GECs and 
immortalized human oral epithelial cells showed an increase in hBD-3 levels upon exposure 
to A. actinomycetemcomitans (Feucht, DeSanti et al. 2003). Similar to HNPs, the peptide has 
also been detected in the GCF of healthy individuals, and a significant decrease in hBD-3 
levels in GCF correlated with the stage of periodontitis, with a negative correlation between 
hBD-3 levels with the number of periopathogenic bacteria within the same site (Bissell, Joly 
et al. 2004; Brancatisano, Maisetta et al. 2011).  
Studies on the regulation of the induction of beta-defensins reveal different ways gingival 
epithelia respond to the presence of pathogenic and non-pathogenic bacteria. Our group has 
reported the induction of hBD-2 by GECs in response to commensal bacteria like F. 
nucleatum and S. gordonii utilized p38 and JNK MAPK pathways, while in response to 
periopathogenic bacteria like P. gingivalis and A. actinomycetemcomitans, GECs utilized the 
NF-κB pathway in addition to the aforementioned MAPK (Krisanaprakornkit, Kimball et al. 
2002; Chung and Dale 2008). Our group has further reported gingival innate immune 
response to P. gingivalis involves Protease-activated receptor-2 (PAR-2), a G-protein coupled 
receptor (Chung, Hansen et al. 2004; Dommisch, Chung et al. 2007). A study from another 
group reported mice given oral doses of P. gingivalis showed alveolar bone loss, but in PAR-
2 deficient mice the amount of bone loss was significantly less, indicating PAR-2 may have a 
role in the inflammatory response against P. gingivalis (Holzhausen, Spolidorio et al. 2006). 
In addition, a recent study revealed that the expression of hBD-3 in response to another 
periodontal pathogen T. denticola is regulated via TLR2 (Shin, Kim et al. 2010). All these 
studies strongly suggest gingival epithelia are able to sense microbes, distinguish between 
commensal and periopathogenic bacteria, and regulate the appropriate responses for 
inflammation via regulation of AMPs.  
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3.1.3 Cathelicidin family – LL-37 
Cathelicidin AMPs are heterogeneous and share similar characteristics with other AMPs, 
such as a basic residue, overall amphipathic nature, and a net positive charge at neutral pH 
(Dale and Fredericks 2005). LL-37, the only member in human cathelicidin family, is 
transcribed by CAMP (cathelicidin antimicrobial peptide) gene, which translates to an 18 
kDa proprotein (Zanetti, Gennaro et al. 2000; Zaiou, Nizet et al. 2003). This AMP is detected 
and expressed in higher amounts within neutrophils that migrate through the junctional 
epithelium to the gingival sulcus (Dale, Kimball et al. 2001). This peptide is present in a 
different site than beta-defensins, suggesting they could serve different role in 
periodontium. The expression of LL-37 is detected in wide range of epithelia and other body 
sites, including junctional epithelium, inflamed epidermal keratinocytes, tongue, buccal 
mucosa and saliva following inflammatory stimulation (Frohm, Agerberth et al. 1997; 
Frohm Nilsson, Sandstedt et al. 1999; Dale, Kimball et al. 2001; Murakami, Ohtake et al. 
2002; Howell 2007). Junctional epithelium also expresses IL-8, following a gradient that 
leads to directional migration of neutrophils into the gingival sulcus when exposed to 
bacteria (Tonetti, Imboden et al. 1994). Thus, it is plausible that neutrophil migration 
through the tissue may be the reason for the expression of LL-37 in gingival epithelium 
(Dale, Kimball et al. 2001; Dale and Fredericks 2005). LL-37 has shown antimicrobial 
activities against periodontal pathogen A. actinomycetemcomitans (Gomez-Garces, Alos et al. 
1994), while is ineffective against some cariogenic bacteria, including S. mutans, Streptococcus 
sobrinus and Actinomyces viscosus, as well as periodontal pathogen P. gingivalis (Altman, 
Steinberg et al. 2006). 
3.2 Differential expression of AMPs in periodontal health and disease 
How the expression of various AMPs varies during gingival and periodontal inflammation 
has been reported by various groups, and these studies show high inter-individual 
variability in both gene and protein expression of AMPs in patient samples (Dunsche, Acil 
et al. 2002; Lu, Jin et al. 2004; Dommisch, Acil et al. 2005; Lu, Samaranayake et al. 2005). 
Analyses of gene expression by RT-PCR showed hBD-1 and hBD-2 mRNA expression was 
less frequently detected in tissues with gingivitis than in healthy gingiva. In biopsies from 
patients with gingivitis, mRNA of hBD-1 and hBD-2 was detectable in 66 % and 86 % of 
samples, respectively, while 100 % of all gingivitis samples showed the expression of hBD-3 
mRNA (Dunsche, Acil et al. 2002). In addition, compared to the samples from healthy 
subjects, the level of beta-defensin mRNA expression was lower and less frequently found 
in samples from periodontitis patients (Dunsche, Acil et al. 2002; Bissell, Joly et al. 2004). 
Similar results have also been reported testing mRNA level by in situ hybridization and 
protein level using immunohistochemistry (Lu, Jin et al. 2004; Lu, Samaranayake et al. 2005; 
Hosokawa, Hosokawa et al. 2006). These studies suggest a decrease in the expression of 
hBD-2 and hBD-3 in both patient groups of gingivitis and periodontitis. However, other 
studies suggest differential expression of beta-defensins in patients with specific periodontal 
diseases, highlighting inter-individual variability in the expression of these AMPs. In 
samples collected from gingivitis and periodontitis patients, the amount of hBD-2 mRNA 
was up-regulated compared to the ones from healthy subjects, while the quantity of hBD-3 
mRNA was equivalent in healthy and gingivitis groups, but increased in periodontitis 
samples (Dommisch, Acil et al. 2005). Quantitative RT-PCR analyses of hBD-1 and hBD-2 
expression levels in gingiva of patients with gingivitis, aggressive periodontitis and chronic 
periodontitis found a significantly higher level of hBD-1 in chronic periodontitis group 
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compared to gingivitis and aggressive periodontitis groups (Vardar-Sengul, Demirci et al. 
2007). On the other hand, the expression level of hBD-2 was significantly higher in 
aggressive periodontitis group than in gingivitis and chronic periodontitis groups (Vardar-
Sengul, Demirci et al. 2007). The localization of beta-defensin protein expression also varied 
among different patient groups. The protein expression of hBD-1 and hBD-2 was mostly 
found in the granular and spinous cell layer in healthy and diseased gingival tissue samples 
(Lu, Jin et al. 2004). On the contrary, the expression of hBD-3 was found in basal cell layer in 
healthy samples, while in the basal and spinous cell layers in samples from periodontal 
disease (Lu, Samaranayake et al. 2005). 
The levels of AMPs in GCF are thought to be associated with periodontal disease, as 
demonstrated by Puklo et al. that the GCF HNP1–3 levels were higher in patients with 
aggressive or chronic periodontitis when compared to healthy controls (Puklo, Guentsch et 
al. 2008). Gingival tissue samples from chronic periodontitis patients showed elevated 
mRNA expression and higher immunostaining of LL-37 on neutrophils, while the LL-37 
levels were also elevated in the GCF of periodontitis patients (Hosokawa, Hosokawa et al. 
2006; Turkoglu, Emingil et al. 2009; Turkoglu, Kandiloglu et al. 2011). In addition, patients 
with morbus Kostmann syndrome, an inherited disorder that causes lower than normal 
levels of neutrophils, have been found to be more susceptible to periodontal disease, while 
those with a bone marrow transplant are not (Putsep, Carlsson et al. 2002). The patients with 
Kostmann syndrome lack LL-37 in saliva and have lower concentrations of HNP1-3, the 
latter of which is commonly found in patients with other neutrophil disorders (Ganz, 
Metcalf et al. 1988). However, when these patients receive a bone marrow transplant, 
normal concentration of LL-37 is found in their saliva (Putsep, Carlsson et al. 2002). Of 
interesting to note is when patients with Kostmann syndrome have their levels of 
neutrophils restored via treatment with recombinant granulocyte-colony stimulating factor, 
they still experience recurring periodontal infections (Putsep, Carlsson et al. 2002; Carlsson, 
Wahlin et al. 2006). All these studies suggest that the deficiency in salivary LL-37 is a likely 
reason for chronic periodontitis in patients with morbus Kostmann prior to bone marrow 
transplant and further suggests a potential protective role in host defense by LL-37. 
All the studies presented in this section demonstrate that AMPs are differentially expressed 
in various stages of periodontal health and disease. These studies also suggest that there 
may be complex regulatory mechanisms involved in gingival innate immunity (Chung, 
Dommisch et al. 2007), and further suggest AMPs play a crucial role in the maintenance of 
gingival health and prevention of periodontal disease. 
3.3 Potential therapeutic value of AMPs 
How AMPs maintain the delicate balance between oral health and dental plaque containing 
microbial consortium is still a matter of conjecture. Some hypotheses include AMPs creating 
physical holes that cause cellular contents to leak out, fatal depolarization of normally 
energized bacterial membrane, or the activation of deadly processes such as the induction of 
hydrolases that degrade the cell wall (Som, Vemparala et al. 2008). Overall, the mode of 
antimicrobial activity of AMPs has been most commonly attributed to disruption of cell 
membranes (Ganz and Lehrer 1999; Hancock and Diamond 2000), but a recent study also 
reported that defensins can inhibit cell wall biosynthesis via binding and sequestering of 
lipid II, a building block of bacterial cell wall (Wilmes, Cammue et al. 2011). 
Currently, a combination of antimicrobial and mechanical applications is used in treatment 
plans for periodontal disease, such as applying tetracycline or doxycline families in 
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conjunction to scaling and root planning. Recently, a sub-antimicrobial dose doxycyline has 
been introduced where low doses are given to block matrix metalloproteinases (MMP), 
which are capable of degrading extracellular matrix proteins (Tuter, Kurtis et al. 2007; 
Payne, Golub et al. 2011). Yet, antibiotic treatment for periodontal disease still poses a risk of 
developing antibiotic-resistant periodontal bacteria in the subgingival plaque (van 
Winkelhoff, Herrera Gonzales et al. 2000; Handal, Caugant et al. 2003; Maestre, Bascones et 
al. 2007; Ardila, Granada et al. 2010). AMPs have several advantages as therapeutics, 
including the broad spectrum of antimicrobial activity and do not appear to induce 
antibiotic resistance. AMPs as therapeutics against microbes would be promising because 
the target of AMPs are the bacterial membrane, thus to combat AMPs the bacteria would 
need to redesign its membrane, which would be a “costly” solution for most species (Zasloff 
2002). The possibility of alleviating bacterial infections related to cystic fibrosis through 
increasing physiological levels of LL-37, or re-engineering human macrophages to express 
beta-defensins to enhance efficacy against Mycobacterium tuberculosis have been proposed 
(Bals, Weiner et al. 1999; Kisich, Heifets et al. 2001). However, limitations as an effective 
therapeutic are stalled by high production costs and the susceptibility to proteolytic 
degradation, a mechanism which microbial pathogens secrete proteases to counter-measure 
the target of AMPs (Peters, Shirtliff et al. 2010). Due to these limitations, a new pursuit has 
been made to construct synthetic mimics of AMPs, which would capture the important 
properties of AMPs but also eliminate problems related to drug therapy. Structurally these 
AMP mimics would maintain its amphiphillic topology to eventually depolarize the 
membrane potential and ultimately kill bacteria, but also possess a non-natural backbone 
without amide or ester function so the peptide will not undergo proteolytic degradation 
from bacterial enzymes (Tew, Liu et al. 2002; Tew, Clements et al. 2006; Hua, Scott et al. 
2010). A recent study showed one mimetic called mPE was able to exhibit potency against 
biofilm cultures of A. actinomycetemcomitans and P. gingivalis, while also inhibiting IL-1B-
induced secretion of IL-8 in gingival epithelial cells (Hua, Scott et al. 2010). The anti-
inflammatory activity was followed with a reduced activation of NF-κB, suggesting that 
these AMP mimics could act as an anti-biofilm and anti-inflammatory agent. Furthermore, it 
has been shown in bacterial resistance studies that Staphylococcus aureus showed increased 
minimum inhibitory concentration (MIC) for conventional antibiotics, but no change was 
observed with MIC for mPE (Beckloff, Laube et al. 2007; Hua, Scott et al. 2010). However, a 
current limitation of mimetic is that it has been tested on single bacterium but not on 
complex biofilm structures.  
4. Proteases vs. protease inhibitors in periodontal health and disease 
4.1 Various classes of protease inhibitors in gingival epithelia 
Serine protease inhibitors play a critical role in host tissue homeostasis, as gingival epithelia 
secrete these protease inhibitors as a way to protect the tissue from excessive damage by 
proteases, which can be of pathogenic bacteria or of neutrophil origin. Thus, the balance 
between proteases and their inhibitors contributes to maintenance of tissue integrity 
(Magert, Drogemuller et al. 2005). These protease inhibitors include secretory leukocyte 
protease inhibitor (SLPI), elastase-specific inhibitor (ELAFIN) and squamous cell carcinoma 
antigen (SCCA). SLPI is found in a variety of mucous secretions, including in GCF from sites 
of periodontal disease (Minami 1999). This protease inhibitor protects tissues from 
destruction during an inflammatory response via regulating the activity of neutrophil 
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elastase (Giannopoulou, Di Felice et al. 1990). ELAFIN, also known as skin-derived anti-
leukoproteinase (SKALP), is expressed in human epithelia of the tongue, palate, lingual 
tonsils, pharynx as well as gingiva (Molhuizen and Schalkwijk 1995). ELAFIN has been 
shown to inhibit neutrophil elastase and proteinase 3, thus has a role in protecting tissue 
from degradation by the neutrophil enzymes (Ying and Simon 1993; Zani, Nobar et al. 2004). 
ELAFIN and SLPI are chelonianin family of serine protease inhibitors and share 40% 
sequence identity (Ying and Simon 1993; Zani, Nobar et al. 2004; Guyot, Butler et al. 2008). 
Both SLPI and ELAFIN have antimicrobial activity against Gram-positive as well as Gram-
negative pathogens (Sallenave, Cunningham et al. 2003; McMichael, Maxwell et al. 2005; 
King, Wheelhouse et al. 2009).  
SCCA1 and SCCA2 are members of the ovalbumin-serpin and serve as a marker for certain 
inflammatory conditions. Within the mucous membranes lined with squamous epithelia, co-
expression of SCCA1 and 2 plays an important role in the coordinated regulation of certain 
serine and cysteine proteases associated with both normal and transformed cells (Cataltepe, 
Gornstein et al. 2000). SCCA1 and SCCA2 share 91% homology at the amino acid level, and 
both are induced by IL-4 and IL-13 (Yuyama, Davies et al. 2002; Mitsuishi, Nakamura et al. 
2005). However, their functions differ: SCCA1 inhibits cysteine proteases such as cathepsin 
K, while SCCA2 inhibits serine proteases such as cathepsin G and human mast cell chymase 
(Silverman, Bird et al. 2001).  
These protease inhibitors are expressed by various epithelial cells and act as an anti-protease 
to protect against tissue damages caused during inflammation (Alkemade, Molhuizen et al. 
1994; Pfundt, van Ruissen et al. 1996; van Wetering, van der Linden et al. 2000). In addition, 
other studies demonstrated anti-bacterial and anti-inflammatory activities of ELAFIN that 
are independent of anti-protease activity (Simpson, Maxwell et al. 1999; Meyer-Hoffert, 
Wichmann et al. 2003). In the context of the periodontium, these protease inhibitors 
produced by GECs might protect against bacterial proteases and limit tissue damage due to 
neutrophil proteases associated with inflammation. Thus, the balance between protease 
inhibitors and proteases may be a factor in the progression of disease. 
4.2 Regulation of protease inhibitors by periodontal pathogens 
The development of periodontal disease is characterized by the transition of the subgingival 
flora from Gram-positive complex, such as Streptococci, to a Gram-negative complex 
including the presumptive pathogen, P. gingivalis (Kolenbrander, Andersen et al. 2002). P. 
gingivalis gingipains are cysteine proteases with specificity for cleavage at either arginine (Rgp) 
or lysine (Kgp) (Potempa, Pike et al. 1995; Potempa and Travis 1996). Rgp activates cellular 
responses of both epithelial cells and fibroblasts via PAR2 and up-regulates inflammatory and 
innate immune responses (Lourbakos, Potempa et al. 2001; Holzhausen, Spolidorio et al. 2006). 
In addition to P. gingivalis, periodontal pathogens T. denticola and T. forsythia also have serine 
or cysteine proteases as their main virulence factors, and these proteases play a role in 
periodontitis (Fenno, Lee et al. 2001; van der Reijden, Bosch-Tijhof et al. 2006). F. nucleatum is a 
common microorganism within the periodontium in both healthy and diseased tissue and 
serves as a bridging organism between commensals and pathogens. Previous studies reported 
F. nucleatum as well as commensal bacterium S. gordonii have serine-type proteases which are 
involved in the degradation of collagen and/or fibronectin (Juarez and Stinson 1999; Bachrach, 
Rosen et al. 2004). In addition to bacterial proteases, neutrophils also release proteases. In the 
normal epithelium, neutrophils flow into the space between the tooth and soft tissue due to the 
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cytokine gradient. Although neutrophils serve as part of the continuous surveillance of the 
gingival sulcus, proteases released by neutrophils contribute to inflammation and tissue 
damage (Tonetti, Imboden et al. 1998; Nathan 2006). 
Our laboratory previously showed that GECs exposed to F. nucleatum up-regulated 
expression of multiple protease inhibitors as well as antimicrobial peptides and other 
potentially protective factors (Table 1) (Yin and Dale 2007). Our data suggest that F. 
nucleatum, a bridging organism between non-pathogenic commensal and pathogenic 
bacteria, enhances expression of protease inhibitors that protect GECs in anticipation of 
virulent proteases secreted by pathogenic bacteria. Both host cell-derived proteases, such as 
neutrophil elastase, and pathogen-derived proteases, such as the gingipains, are targeted by 
these protease inhibitors, and therefore, the protease inhibitors may play an important role 
in maintaining the extent of inflammatory tissue damage (Into, Inomata et al. 2006; 
Williams, Brown et al. 2006; Yin, Swanson et al. 2010).  
 
Protease 
Inhibitor 
Target Protease Potential Function Fold 
Change* 
ELAFIN Elastase, PMN Innate immunity, 
antimicrobial 
14.31 
SERPINB1 Elastase, Cathepsin 
G 
Innate immunity, inhibits 
PMN proteases 
3.2 
SERPINB2 Thrombin Regulates extravascular 
plasminogen activation 
2.2 
SCCA1 Cathepsin S, K, L Inhibits Cathepsin S, K, L 
and modulates host 
immune response 
19.4 
SCCA2 Cathepsin G Inhibits mast cell proteases 8.6 
SLPI Elastase, Trypsin, 
Cathepsin B 
Stimulates wound healing, 
inhibits PMN proteases 
4.3 
Cystatin B Stefin B Protection against 
intracellular proteases 
2.0 
*Fold increase after stimulation with F. nucleatum cell wall extract for 24h compared to unstimulated. 
Table 1. Changes in the induction level of various protease inhibitors in gingival epithelial 
cells following stimulation with F. nucleatum (Yin and Dale 2007). 
These protease inhibitors are also affected by perio-pathogenic organism P. gingivalis, whose 
main virulence factors are cysteine proteases. A protective effect of these protease inhibitors in 
gingival health is shown by our study that demonstrated pre-treatment of GECs with SLPI, 
SCCA1 or SCCA2 partially attenuated antimicrobial proteins hBD-2 and CCL20 mRNA 
expression in response to P. gingivalis (Yin, Swanson et al. 2010). However, the same study 
showed the presence of P. gingivalis disrupted the function of these serine protease inhibitors, 
suggesting that the presence of an organism colonizing oral plaque prior to the establishment 
by pathogens enhances expression of protease inhibitors that protect GECs, while P. gingivalis 
secretes proteases that degrade cellular protease inhibitors (Yin, Swanson et al. 2010). It is of 
interest to note that various periodontal pathogens which secrete proteases (P. gingivalis, T. 
forsythia, A. actinomycetemcomitans) were tested, but P. gingivalis was most effective at 
degrading protease inhibitors (Figure 2) (Yin, Swanson et al. 2010). The degradation of 
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protease inhibitors by P. gingivalis may result in decreased host protective capacity, and the 
balance between cellular protease inhibitors and their degradation by P. gingivalis and/or 
other periodontal pathogens may be an important factor in susceptibility to P. gingivalis 
infection. The dominance of P. gingivalis in the degradation of protease inhibitors is important 
to note, since during the formation of dental plaque, protease inhibitors may be induced as a 
host protective mechanism by the presence of non-pathogenic bacteria, but may become 
ineffective once protease-secreting pathogens are established.  
 
 
Fig. 2. Recombinant SLPI, ELAFIN, SCCA1, and SCCA2 are degraded by P. gingivalis 
supernatants in vitro in a dose-dependent manner. Western Blot analysis for each protease 
inhibitor using a constant concentration of recombinant protease inhibitor incubated with cell-
free supernatants of oral bacteria for 15 min at RT. The undiluted supernatant (1) corresponds 
to MOI 100; increasing dilution factor is indicated below each protease inhibitor. Control: 
recombinant protein only. The controls shown with P. gingivalis also apply to the recombinant 
proteins treated with T. forsythia and F. nucleatum (Yin, Swanson et al. 2010). Permission from 
Co-Action Publishing. 
In addition to exposure to proteases secreted by oral pathogenic bacteria, oral cavity may also 
be exposed to different neutrophil-derived serine proteases, such as human leukocyte elastase, 
cathepsin G and proteinase 3 (Sugawara, Uehara et al. 2001; Uehara, Muramoto et al. 2003). 
These neutrophil proteases may be secreted in response to the presence of oral bacteria, and 
thus oral cavity may be exposed to these neutrophil proteases prior to being exposed to 
proteases from periodontal pathogens. In addition, protease inhibitors are likely to have 
different effects on neutrophil proteases secreted by host vs. proteases secreted by periodontal 
pathogens: proteases secreted by pathogens may degrade host protease inhibitors; while 
proteases secreted by host neutrophils may maintain more natural balance in maintaining 
epithelial health. Proteases have to be at the right place at the right time to have an effect on 
the host, thus have to be tightly regulated by the host. Therefore, the balance between the 
proteases and protease inhibitors is crucial in the health of oral epithelia. 
4.3 Changes in protease inhibitor levels in periodontitis 
Periodontitis is a chronic inflammatory disease whose main etiologic agents include Gram-
negative anaerobic bacteria and spirochetes (Haffajee and Socransky 1994). Among them, P. 
gingivalis in particular plays a significant role in the progression of chronic periodontitis 
(O'Brien-Simpson, Veith et al. 2004). Many virulence factors of this pathogen include 
proteases (gingipains), fimbriae and hemagglutinins (Amano 2003; Veith, Chen et al. 2004; 
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Into, Inomata et al. 2006). P. gingivalis gingipains have shown to degrade extracellular matrix 
components such as laminin, fibronectin, and collagen type III, IV, and V in vitro (Potempa, 
Banbula et al. 2000), and are thought to account for at least 85% of the general proteolytic 
activity displayed by P. gingivalis (Imamura 2003). Our previous in vitro study found that the 
secretion of SLPI and ELAFIN was significantly reduced in response to P. gingivalis and that 
P. gingivalis supernatants digested recombinant SLPI, ELAFIN, SCCA1 and 2 (Figure 2) (Yin, 
Swanson et al. 2010). These data suggest degradation of protease inhibitors by P. gingivalis 
may result in decreased host protective capacity and higher susceptibility to P. gingivalis 
infection (Yin, Swanson et al. 2010).  
As a follow-up to this in vitro study, an in vivo study from our group correlated the amount 
of P. gingivalis in subgingival plaque of patients with chronic periodontitis with the level of 
protease inhibitors in GCF of healthy and periodontitis patients. Significantly lower levels of 
SLPI and ELAFIN were detected in subjects with periodontitis and P. gingivalis present in 
their plaque compare to healthy controls (Kretschmar, Yin et al. 2011). The level of SLPI was 
also decreased in GCF of periodontal patients without detectable level of P. gingivalis in their 
subgingival plaque. And an inverse correlation was observed between the ELAFIN and 
SLPI concentrations and the number of P. gingivalis present in subgingival plaque. Our 
findings showed that host-derived protease inhibitors SLPI and ELAFIN, which are secreted 
as a response to environmental and microbial stimuli, are decreased in concentration in 
periodontal pockets with P. gingivalis. The reduced concentrations of these protective 
protease inhibitors may contribute to the loss of host defense capacity and increase 
susceptibility to breakdown from chronic infection.  
Similarly, a separate study reported when SLPI concentrations in GCF from active 
periodontitis patients and periodontitis patients in maintenance were compared, SLPI was 
significantly reduced in the group with high amount of P. gingivalis (Into, Inomata et al. 
2006). The proteolytic activity of P. gingivalis gingipain isoform RgpA is thought to be 
responsible for this observation (Into, Inomata et al. 2006). Although the overall bacterial 
load in these samples was not specified, the data from this study is in agreement with our 
previous study utilizing P. gingivalis mutant strains lacking various gingipains (Yin, 
Swanson et al. 2010). In addition to the role RgpA may play in the degradation of SLPI, the 
bacterial biofilm may also play a role in the degradation of protease inhibitors, such as 
increased neutrophil elastase level as a result of high bacterial load in dental plaque. 
5. Epigenetic regulation and its implication on periodontal disease 
Epigenetics is heritable and reversible changes in gene expression without altering DNA 
sequence. Chromatin structure is made up of eight histone molecules (two each of H2A, H2B, 
H3 and H4) and DNA which winds around these proteins. Histones are subject to a number of 
post-translational modifications, such as acetylation, methylation, phosphorylation and 
ubiquitination (Hansen, Tse et al. 1998; Strahl and Allis 2000). The mechanisms of epigenetic 
modifications include histone acetylation, histone methylation and DNA methylation, and 
these modifications provide a way to control the expression of genes involved in various 
cellular functions as well as in cancer (Egger, Liang et al. 2004; Rodenhiser and Mann 2006). 
Enzymes involved in these epigenetic mechanisms are: histone acetyltransferases (HATs); 
histone deacetylases (HDACs); histone methyltransferases (HMTs); and DNA 
methyltransferases (DNMTs) (Figure 3). Modifications on chromatin structure can occur in 
response to diet, inherited polymorphisms in certain genes and to environmental toxins 
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(Sutherland and Costa 2003; Luch 2005; Rodenhiser and Mann 2006). When histones are 
acetylated, transcription factors can access DNA, leading to gene transcription, while 
deacetylated histones lead to condensed (or closed) chromatin structure, making DNA 
inaccessible to transcription factors and preventing gene expression (Figure 3). In addition, 
methylation of cytosine residues at CpG sites in DNA inhibits binding of transcription factors, 
leading to gene silencing. Methylation of gene promoter region is one of the most common 
epigenetic mechanisms in silencing tumor suppressor genes, and over-expression of DNMTs 
in humans is associated with a variety of cancers (Rodenhiser and Mann 2006). Furthermore, 
decreased methyltransferase activity and hypo-methylated DNA have been associated with 
autoimmune diseases (Richardson 2003; Oelke and Richardson 2004), and changes in the histone 
acetylation in central nervous system has been linked to cognitive decline in a mouse model 
(Peleg, Sananbenesi et al. 2010). Although various epigenetic mechanisms work in concert to 
produce long-term and stable regulation of gene expression, not much is known on how these 
processes are linked and how specific patterns of epigenetic modification are inherited.  
A recent study reported that oral squamous cell carcinoma showed epigenetic changes 
associated with SERPINE1 expression (Gao, Nielsen et al. 2010), while other studies suggest 
that epigenetics play a critical role in regulating inflammatory responses and that the 
manifestation and severity of periodontal disease may be influenced by epigenetic factors 
(Bobetsis, Barros et al. 2007; Offenbacher, Barros et al. 2008). Many patients with the same 
clinical symptoms respond differently to the same therapy, suggesting the inter-individual 
variability observed as a clinical outcome of the disease is influenced by genetic (Schenkein 
2002; Feinberg 2007) as well as epigenetic factors (Offenbacher, Barros et al. 2008). 
Epigenetic modifications alter patterns of gene expression, which in turn leads to various 
clinical outcomes. Furthermore, variations in epigenetic status will likely elicit diverse 
inflammatory responses. A new study from our group focused on finding answers to how 
epigenetic modifications brought on by exposure to oral bacteria, including periodontal 
pathogens, affect host innate immune responses and susceptibility to subsequent infections 
(Yin and Chung 2011).  
 
Fig. 3. Histone acetylation allows open chromatic structure, and transcription factors can 
access DNA. Deacetylation of histones as well as histone methylation and DNA methylation 
result in closed chromatin, thus transcription factors cannot access DNA, which results in 
gene silencing. Epigenetic modifications of histones and/or DNA via methylation lead to 
altered gene expression. TF: transcription factors; Ac: acetylation; Me: methylation; HAT: 
histone acetyltransferase; HDAC: histone deacetylase; HMT: histone methyltransferase; 
DNMT: DNA methyltransferase. 
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When any changes in the expression levels of enzymes involved in the epigenetic 
modification after GECs were exposed to oral bacteria were investigated, we found the 
expression of histone deacetylases and DNA methyltransferase changed in response to the 
presence of oral bacteria. Histone deacetylases (HDACs) remove acetyl groups from histone, 
leading to suppression of genes, while DNA methyltransferases (DNMTs) catalyze transfer 
of methyl groups onto DNA, which also leads to gene suppression (Figure 3). Quantitative 
real-time PCR analyses showed changes in the expression levels of these genes when GECs 
were treated with P. gingivalis or F. nucleatum at various multiplicities of infection for 1, 4, 24 
and 48 h. The gene expression levels of DNMT1, HDAC1 and HDAC2 decreased in GECs 
treated with P. gingivalis or F. nucleatum, although the levels of decrease differed between 
bacterial species and/or exposure time (Yin and Chung 2011). As changes in the expression 
of enzymes catalyzing epigenetic modifications were observed, it was also of interest to note 
the changes in methylation levels of various genes in GECs after the cells were exposed to 
these oral bacteria. Studies utilizing methylation PCR Array showed a dose-dependent and 
statistically significant increase in methylation levels of the following genes after GECs were 
exposed to P. gingivalis: CD276, an immune regulator; elastase 2, a serine protease that plays 
a role in inflammatory diseases; INHBA, a tumor-suppressing protein; GATA 3, a putative 
tumor suppressor; TLR2; and IL-12A. Stimulation of GECs with P. gingivalis also resulted in 
hypo-methylation of ZNF287, a member of Zinc finger protein family. The up-regulation of 
Zinc finger proteins has been associated with cardiovascular disease (Dai and Liew 1999), 
thus this observation is in line with recent studies linking periodontal disease with increased 
risk of systemic disease (Persson and Persson 2008). GECs exposed to P. gingivalis also 
showed a decrease in the methylation of STAT5A, which mediates cellular responses to 
cytokines IL-2, IL-3, IL-7, GM-CSF and plays a role in progression of tumors. On the other 
hand, the methylation levels of elastase 2 and GATA3 decreased significantly after cells 
were stimulated with F. nucleatum (Yin and Chung 2011). Interestingly, only F. nucleatum 
induced hyper-methylation of MALT1 (Mucosa-associated lymphoid tissue lymphoma 
translocation gene) in GECs. MALT1 induces IKK catalytic activity, resulting in NFκB 
activation in immune cells (Schulze-Luehrmann and Ghosh 2006). The methylation of 
MALT1 is associated with silencing of MALT1 gene, which is consistent with our previous 
reports that F. nucleatum does not utilize the NFκB signaling pathway in the induction of 
innate immune responses (Chung and Dale 2004; Chung and Dale 2008). Taken together, 
these data suggest that epigenetic modification of genes, whose function is associated with 
growth control and inflammation, is differentially regulated by different oral bacteria (Yin 
and Chung 2011).  
Modulations of chromatin structure play an important role in the regulation of transcription, 
and these modifications directly affect the accessibility of chromatin to transcription factors, 
thus on gene expression. When the changes in histone H3 level in GECs after exposure to 
periopathogen vs. non-pathogen were examined, the endogenous level of histone H3 that is 
tri-methylated at Lys4 was significantly decreased following stimulated with P. gingivalis 
compared to unstimulated control, while the level increased after exposure to F. nucleatum 
(Yin and Chung 2011). Our data suggest these two bacterial species, pathogen vs. non-
pathogen, differentially regulate H3K4 methylation and further suggest bacterial infection in 
oral epithelia is associated with changes in H3K4 methylation (Yin and Chung 2011). 
Gene promoter methylation is the most common epigenetic mechanism silencing tumor 
suppressor genes during oncogenesis. Almost all cancer-related signaling pathways are 
affected by methylation, and the number of genes affected in each major type of cancer is 
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still rapidly growing. However, even the most relevant genes have not yet been correlated to 
individual cancer types for development of DNA methylation biomarkers. Recent studies 
reported that particular histone modifications are correlated with certain types of cancers 
and that histone modifications will be useful biomarkers for cancer (Su, Lucas et al. 2009; 
Manuyakorn, Paulus et al. 2010; Svotelis, Gevry et al. 2010). Since our recent data strongly 
suggest presence of oral bacteria affects chromatin modification in GECs, it is plausible 
periodontal patients with high number of periodontal pathogens recovered from the oral 
cavity will show altered chromatin modifications. Further studies are needed to identify 
epigenetic factors involved in development and pathogenesis of periodontitis, contributing 
to better defining of epigenetic modifications as an indicator of periodontal disease. It would 
be of importance in a periodontal treatment plan to identify a certain species of bacteria 
which induce epigenetic changes and subsequently modify host responses. Furthermore, 
better understanding of specific bacteria that show capacity to induce epigenetic changes 
would be of importance in developing specific therapeutic strategies for each patient. 
6. Conclusion 
Periodontitis is a disease that is not only caused by one single bacterium, but by a number of 
different bacterial species, organized in a complex biofilm and thereby exhibiting various 
properties. Understanding how gingival epithelia response to the presence of different 
commensals and pathogens, leading to induction of appropriate innate immune responses, 
will provide significant new insights into this complex biological system in the oral 
epithelia. Furthermore, better understanding the role of other factors influencing 
periodontal health, such as the balance between proteases and protease inhibitors, and the 
role epigenetic status plays in health and disease, will have direct implications for new 
understanding of oral innate immune responses and the development of potential new and 
innovative therapeutic interventions for periodontal disease. 
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